$BLUE
bluebird bio, Inc. Stock $blue

$blue Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000129397124000079 Filed on November 14, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$10.61M
YoY Change		-14.36%
Cost Of Revenue		$11.78M
YoY Change		7.54%
Gross Profit		-$1.169M
YoY Change		-181.35%
Gross Profit Margin		-11.02%
Selling, General & Admin		$39.77M
YoY Change		-2.3%
% of Gross Profit
Research & Development		$23.17M
YoY Change		-49.03%
% of Gross Profit
Depreciation & Amortization		$15.34M
YoY Change		1334.02%
% of Gross Profit
Operating Expenses		$62.94M
YoY Change		-26.96%
Operating Profit		-$66.92M
YoY Change		-21.02%
Interest Expense		-$4.138M
YoY Change		-268.62%
% of Operating Profit
Other Income/Expense, Net		$10.19M
YoY Change		-3.35%
Pretax Income		-$60.87M
YoY Change		-15.15%
Income Tax		-$100.0K
% Of Pretax Income
Net Earnings		-$60.81M
YoY Change		-15.23%
Net Earnings / Revenue		-573.01%
Basic Earnings Per Share		-$0.31
Diluted Earnings Per Share		-$0.31
COMMON SHARES
Basic Shares Outstanding	194.4M shares	193.9M shares
Diluted Shares Outstanding		193.9M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$70.65M
YoY Change		-59.46%
Cash & Equivalents		$70.65M
Short-Term Investments
Other Short-Term Assets		$25.15M
YoY Change		44.7%
Inventory		$53.94M
Prepaid Expenses		$7.553M
Receivables
Other Receivables
Total Short-Term Assets		$150.8M
YoY Change		-38.96%
LONG-TERM ASSETS
Property, Plant & Equipment		$62.59M
YoY Change		527.69%
Goodwill		$5.646M
YoY Change		0.0%
Intangibles		$9.780M
YoY Change		82.19%
Long-Term Investments
YoY Change
Other Assets		$53.13M
YoY Change		4.52%
Total Long-Term Assets		$314.2M
YoY Change		-14.27%
TOTAL ASSETS
Total Short-Term Assets		$150.8M
Total Long-Term Assets		$314.2M
Total Assets		$465.1M
YoY Change		-24.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$24.48M
YoY Change		23.32%
Accrued Expenses		$87.50M
YoY Change		-27.98%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due		$70.60M
YoY Change
Total Short-Term Liabilities		$296.0M
YoY Change		86.23%
LONG-TERM LIABILITIES
Long-Term Debt		$5.675M
YoY Change
Other Long-Term Liabilities		$1.079M
YoY Change		1072.83%
Total Long-Term Liabilities		$1.079M
YoY Change		1072.83%
TOTAL LIABILITIES
Total Short-Term Liabilities		$296.0M
Total Long-Term Liabilities		$1.079M
Total Liabilities		$470.8M
YoY Change		20.4%
SHAREHOLDERS EQUITY
Retained Earnings		-$4.500B
YoY Change		9.49%
Common Stock		$1.917M
YoY Change		78.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		-$5.786M
YoY Change
Total Liabilities & Shareholders Equity		$465.1M
YoY Change		-24.21%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$60.81M
YoY Change		-15.23%
Depreciation, Depletion And Amortization		$15.34M
YoY Change		1334.02%
Cash From Operating Activities		-$68.93M
YoY Change		11.44%
INVESTING ACTIVITIES
Capital Expenditures		$280.0K
YoY Change		-86.21%
Acquisitions
YoY Change
Other Investing Activities		$746.0K
YoY Change		-98.84%
Cash From Investing Activities		$466.0K
YoY Change		-99.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-6.105M
YoY Change		15162.5%
NET CHANGE
Cash From Operating Activities		-68.93M
Cash From Investing Activities		466.0K
Cash From Financing Activities		-6.105M
Net Change In Cash		-74.57M
YoY Change		-39345.79%
FREE CASH FLOW
Cash From Operating Activities		-$68.93M
Capital Expenditures		$280.0K
Free Cash Flow		-$69.21M
YoY Change		8.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1079000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	92000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	192772000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	192772000	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	1917000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1905000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4466141000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4454756000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1511000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1796000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4472333000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4260328000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-5786000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	194537000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	465056000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	619161000	usd
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001293971
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	bluebird bio, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	13-3680878
	dei	Entity Address Address Line1 EntityAddressAddressLine1	455 Grand Union Boulevard
	dei	Entity Address City Or Town EntityAddressCityOrTown	Somerville
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02145
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	194444345	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	70651000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	221755000	usd
CY2024Q3	blue	Receivables And Other Current Assets ReceivablesAndOtherCurrentAssets	17601000	usd
CY2023Q4	blue	Receivables And Other Current Assets ReceivablesAndOtherCurrentAssets	21651000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	150811000	usd
CY2024Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	70179000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	73188000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	134333000	usd
	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	296032000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	200113000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	168056000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	186687000	usd
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	193917000	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	193917000	shares
CY2024Q3	us-gaap	Revenues Revenues	10612000	usd
CY2023Q3	us-gaap	Revenues Revenues	12392000	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	11781000	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	-1169000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	3266000	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	39765000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23174000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	58501000	usd
CY2023Q3	us-gaap	Restructuring Charges RestructuringCharges	0	usd
CY2024Q3	us-gaap	Costs And Expenses CostsAndExpenses	65750000	usd
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	99272000	usd
CY2024Q3	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	usd
CY2023Q3	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-66919000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-96006000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	611000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	984000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	14600000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	26197000	usd
	blue	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-18686000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-248000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2975000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
	us-gaap	Proceeds From Sales Of Assets Investing Activities ProceedsFromSalesOfAssetsInvestingActivities	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1432000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	274597000	usd
	dei	Amendment Flag AmendmentFlag	false
	dei	City Area Code CityAreaCode	339
	dei	Local Phone Number LocalPhoneNumber	499-9300
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7553000	usd
CY2024Q3	blue	Factoring Agreement Receivable Current FactoringAgreementReceivableCurrent	1062000	usd
CY2023Q4	blue	Factoring Agreement Receivable Current FactoringAgreementReceivableCurrent	560000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	281685000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	62593000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	5646000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	10438000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	183098000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	201113000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	53128000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	54343000	usd
CY2024Q3	us-gaap	Assets Assets	465056000	usd
CY2023Q4	us-gaap	Assets Assets	619161000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	24481000	usd
CY2024Q3	blue	Factoring Agreement Payable Current FactoringAgreementPayableCurrent	10080000	usd
CY2023Q4	blue	Factoring Agreement Payable Current FactoringAgreementPayableCurrent	2520000	usd
CY2024Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	5675000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	37732000	usd
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10612000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12281000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	131536000	usd
CY2024Q3	us-gaap	Restructuring Charges RestructuringCharges	2811000	usd
	dei	Trading Symbol TradingSymbol	BLUE
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
CY2023Q4	us-gaap	Inventory Net InventoryNet	22919000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	65936000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	18498000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	24511000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	0	usd
CY2023Q3	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	111000	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	12000	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	249000	usd
	us-gaap	Revenues Revenues	45286000	usd
	us-gaap	Revenues Revenues	21663000	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	9126000	usd
	us-gaap	Gross Profit GrossProfit	-21305000	usd
	us-gaap	Gross Profit GrossProfit	328000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	136479000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	118700000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	73408000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	285000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1843000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	14800000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	53944000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	5646000	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9780000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21202000	usd
CY2024Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	96181000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	84705000	usd
CY2024Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	70600000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2024Q3	us-gaap	Liabilities Liabilities	470842000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	424624000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45274000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21414000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	66591000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	21335000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	40771000	usd
	us-gaap	Restructuring Charges RestructuringCharges	2811000	usd
	us-gaap	Restructuring Charges RestructuringCharges	0	usd
	us-gaap	Costs And Expenses CostsAndExpenses	212698000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	250236000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	92930000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-234003000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-156978000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	1640000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2454000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	7056000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	7961000	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	5778000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	4311000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	16875000	usd
	us-gaap	Interest Expense InterestExpense	12331000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10191000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10631000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	31782000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	30177000	usd
CY2024Q3	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-60866000	usd
CY2023Q3	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-87232000	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-212040000	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-131171000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-58000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-37000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-80000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-60808000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-87232000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-212003000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-131091000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.80
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.10
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.23
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.80
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.10
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.23
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	193893000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	109098000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	193588000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106924000	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	193893000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	109098000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	193588000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106924000	shares
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0.0	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0.0	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0.0	usd
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0.0	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	137000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	611000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	137000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	285000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1843000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-60197000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-87095000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-211718000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-129248000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	194537000	usd
CY2024Q1	blue	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	0	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2571000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4054000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-312000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-69804000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	131046000	usd
CY2024Q2	blue	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	0	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	81000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3261000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-14000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-81393000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	52981000	usd
CY2024Q3	blue	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	0	usd
CY2024Q3	blue	Adjustments To Additional Paid In Capital Warrant Reclassification AdjustmentsToAdditionalPaidInCapitalWarrantReclassification	1945000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3375000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	611000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-60808000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-5786000	usd
CY2023Q1	blue	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	-195000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	227000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	130291000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5843000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	18930000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	290420000	usd
CY2023Q2	blue	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	0	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	77000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6388000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	722000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-62789000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	234818000	usd
CY2023Q3	blue	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	0	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-50000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5153000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	137000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-87232000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	152834000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-212003000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-131091000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	47339000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	19660000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9669000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	16013000	usd
	blue	Noncash Research And Development Expense Finance Lease NoncashResearchAndDevelopmentExpenseFinanceLease	0	usd
	blue	Noncash Research And Development Expense Finance Lease NoncashResearchAndDevelopmentExpenseFinanceLease	22223000	usd
	blue	Noncash Lease Expense NoncashLeaseExpense	18015000	usd
	blue	Noncash Lease Expense NoncashLeaseExpense	23965000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	92930000	usd
	blue	Inventory Excess Valuation Reserves InventoryExcessValuationReserves	8035000	usd
	blue	Inventory Excess Valuation Reserves InventoryExcessValuationReserves	9202000	usd
	blue	Noncash Interest Related To Debt NoncashInterestRelatedToDebt	-1916000	usd
	blue	Noncash Interest Related To Debt NoncashInterestRelatedToDebt	0	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	14000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-100000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	86000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1062000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	47022000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2117000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	38038000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6660000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1712000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2986000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5709000	usd
	blue	Increase Decrease Accrued Interest Payable Under Finance Lease IncreaseDecreaseAccruedInterestPayableUnderFinanceLease	-8010000	usd
	blue	Increase Decrease Accrued Interest Payable Under Finance Lease IncreaseDecreaseAccruedInterestPayableUnderFinanceLease	-3203000	usd
	blue	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-15323000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-209856000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-180910000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2114000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	43297000	usd
	blue	Factoring Agreement Cash Receipts Collected Net Of Fees FactoringAgreementCashReceiptsCollectedNetOfFees	3546000	usd
	blue	Factoring Agreement Cash Receipts Collected Net Of Fees FactoringAgreementCashReceiptsCollectedNetOfFees	0	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	99521000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	5853000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	868000	usd
	us-gaap	Proceeds From Sales Of Assets Investing Activities ProceedsFromSalesOfAssetsInvestingActivities	92930000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	151164000	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	71316000	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2669000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	2576000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	93000	usd
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	50646000	usd
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	0	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	69576000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	40299000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	52479000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	89670000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-155945000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	59924000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	158445000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	118652000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	218369000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	70651000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	165347000	usd
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	4360000	usd
CY2023Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	8885000	usd
CY2024Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	43641000	usd
CY2023Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	44137000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	118652000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	218369000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	31000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	941000	usd
	blue	Offering Expenses Included In Accounts Payable And Accrued Expenses OfferingExpensesIncludedInAccountsPayableAndAccruedExpenses	0	usd
	blue	Offering Expenses Included In Accounts Payable And Accrued Expenses OfferingExpensesIncludedInAccountsPayableAndAccruedExpenses	248000	usd
	blue	Right Of Use Asset Obtained In Exchange For Operating Lease Liability Including Adjustments For Remeasurement RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityIncludingAdjustmentsForRemeasurement	0	usd
	blue	Right Of Use Asset Obtained In Exchange For Operating Lease Liability Including Adjustments For Remeasurement RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityIncludingAdjustmentsForRemeasurement	-708000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	41893000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	21508000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-10000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	5000	usd
	blue	Beneficiary Interest Obtained In Transferred Invoices BeneficiaryInterestObtainedInTransferredInvoices	4850000	usd
	blue	Beneficiary Interest Obtained In Transferred Invoices BeneficiaryInterestObtainedInTransferredInvoices	0	usd
	blue	Beneficial Interest Amount Derecognized BeneficialInterestAmountDerecognized	43650000	usd
	blue	Beneficial Interest Amount Derecognized BeneficialInterestAmountDerecognized	0	usd
	us-gaap	Nature Of Operations NatureOfOperations	Description of the business<div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bluebird bio, Inc. (the “Company” or “bluebird”) was incorporated in Delaware on April 16, 1992, and is headquartered in Somerville, Massachusetts. The Company is a biotechnology company committed to researching, developing and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector ("LVV") gene addition platform. Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its product candidates, and commercialization of its approved products, including activities to manufacture product candidates, conduct clinical studies of its product candidates, perform preclinical research to identify new product candidates, provide selling, general and administrative support for these operations and market and commercially manufacture and distribute its approved products.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s programs in severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel, also known as beti-cel) as a treatment for β-thalassemia; LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel) as a treatment for sickle cell disease ("SCD"); and SKYSONA (elivaldogene autotemcel, also known as eli-cel) as a treatment for cerebral adrenoleukodystrophy ("CALD"). On August 17, 2022, ZYNTEGLO was approved by the U.S. Food and Drug Administration ("FDA") for the treatment of adult and pediatric patients with ß-thalassemia who require regular red blood cell transfusions. On September 16, 2022, the FDA granted Accelerated Approval of SKYSONA to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active CALD. On December 8, 2023, LYFGENIA was approved by the FDA for the treatment of patients 12 years of age or older with sickle cell disease and with a history of vaso-occlusive-events. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company entered into an Open Market Sales Agreement (the "Sales Agreement") with Jefferies LLC ("Jefferies") to sell shares of the Company’s common stock up to $125.0 million, from time to time, through an “at the market” equity offering program under which Jefferies will act as sales agent. As of September 30, 2024, the Company has made no sales pursuant to the Sales Agreement.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC ("Goldman") and J.P. Morgan Securities LLC, to sell 83.3 million shares of the Company's common stock. The Company received net proceeds of approximately $118.1 million. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the Company entered into a five-year term loan facility agreement with Hercules Capital, Inc. to secure debt financing for up to $175.0 million, available in four tranches. This is described in Note 8,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Term Loan Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the Notes to Condensed Consolidated Financial Statements appearing elsewhere in this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2024, the Company's board of directors approved a restructuring action (the "Restructuring") following a comprehensive review of the Company's operations, which resulted in a reduction of the Company's workforce by 94 employees, or approximately 25% of employees. The Restructuring is designed to support the Company's commercial focus and reduce its cash operating expenses. Refer to Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reduction in workforce, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for more information on the Restructuring.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has incurred significant operating losses and negative operating cash flows. As of September 30, 2024, the Company had an accumulated deficit of $4.5 billion. During the nine months ended September 30, 2024, the Company incurred a net loss of $212.0 million and used $209.9 million of cash in operations. As of September 30, 2024, the Company had cash and cash equivalents of $70.7 million. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (“ASC”) 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's history of recurring operating losses and negative operating cash flows, its expectation to generate operating losses and negative operating cash flows, its projection that it may not maintain the minimum cash coverage related to </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Loan and Security Agreement (the “LSA”), and the need for additional funding to support its planned operations raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date that these consolidated financial statements are issued. Management's plans to alleviate the conditions that raise substantial doubt include controlling spending, executing on commercial launch plans, and exploring additional financing options. Management has concluded the likelihood that its plan to successfully obtain sufficient funding from one or more of these sources, or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for a period of at least 12 months from the date of issuance of these consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has based the estimated cash needs on assumptions that may prove to be wrong, and its operating plan may change as a result of many factors currently unknown to it. As a result, the Company could deplete its capital resources sooner than it currently expects. Along with the Company's revenue from product sales, the Company expects to finance its future cash needs through the issuance of equity, or debt, or other alternative means. If the Company is unable to obtain funding on a timely basis, or if revenues from product sales are less than it has projected, the Company may be required to further revise its business plan and strategy, which may result in the Company significantly curtailing, delaying or discontinuing one or more of its research or development programs or the commercialization of any products or may result in the Company being unable to continue or expand its operations or otherwise capitalize on its business opportunities. As a result, the Company's business, financial condition and results of operations could be materially affected. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.</span></div>
CY2024Q1	blue	Number Of Tranches NumberOfTranches	4	tranche
CY2024Q3	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	94	employee
CY2024Q3	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.25
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4500000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-212000000.0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-209900000	usd
CY2024Q3	us-gaap	Investments And Cash InvestmentsAndCash	70700000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification of Prior Year Presentation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to the current year presentation. Specifically, interest expense has been reclassified from interest income to interest expense in the consolidated statement of operations and comprehensive loss. These reclassifications had no effect on the reported results of operations.</span></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates and judgments are used in the following areas, among others: the alternative future use of assets used in research and development activities, realizability of inventories, future undiscounted cash flows and subsequent fair value estimates used to assess potential and measure any impairment of long-lived assets, including goodwill and intangible assets, and the measurement of right-of-use assets and lease liabilities, gross-to-net revenue calculations, stock-based compensation expense, accrued expenses, income taxes, the assessment of the Company's ability to fund its operations for at least the next twelve months from the date of issuance of these financial statements, and the assessment of the likelihood and magnitude of losses that may be sustained upon resolution of contingencies.</span></div>
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10600000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12300000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45300000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21400000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10612000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12281000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45274000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21414000	usd
CY2023Q4	blue	Contract With Customer Rebate Liability Current ContractWithCustomerRebateLiabilityCurrent	5365000	usd
	blue	Provision For Contract With Customer Rebate Liability ProvisionForContractWithCustomerRebateLiability	8506000	usd
	blue	Contract With Customer Payments Rebate Liability ContractWithCustomerPaymentsRebateLiability	0	usd
CY2024Q3	blue	Contract With Customer Rebate Liability Current ContractWithCustomerRebateLiabilityCurrent	13871000	usd
CY2024Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2965000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2329000	usd
CY2024Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	48649000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	17375000	usd
CY2024Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2330000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3215000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	53944000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	22919000	usd
CY2024Q3	blue	Factoring Agreement Percentage Of Invoice Sold FactoringAgreementPercentageOfInvoiceSold	1
CY2024Q3	blue	Factoring Agreement Upfront Purchase Price As A Percentage Of Invoice Amount FactoringAgreementUpfrontPurchasePriceAsAPercentageOfInvoiceAmount	0.90
CY2024Q3	blue	Factoring Agreement Remaining Percentage Of Invoice Amount Payable Upon Receipt Of Full Payment FactoringAgreementRemainingPercentageOfInvoiceAmountPayableUponReceiptOfFullPayment	0.10
CY2024Q3	blue	Factoring Agreement Cash Receipts Collected Prior To Consideration FactoringAgreementCashReceiptsCollectedPriorToConsideration	15200000	usd
	blue	Factoring Agreement Cash Receipts Collected Prior To Consideration FactoringAgreementCashReceiptsCollectedPriorToConsideration	50600000	usd
CY2024Q3	blue	Factoring Agreement Payable Current Derecognized FactoringAgreementPayableCurrentDerecognized	10600000	usd
	blue	Factoring Agreement Payable Current Derecognized FactoringAgreementPayableCurrentDerecognized	43700000	usd
CY2024Q3	blue	Beneficiary Interest Obtained BeneficiaryInterestObtained	1200000	usd
	blue	Beneficiary Interest Obtained BeneficiaryInterestObtained	4900000	usd
CY2024Q3	blue	Factoring Agreement Cash Receipts Collected FactoringAgreementCashReceiptsCollected	700000	usd
	blue	Factoring Agreement Cash Receipts Collected FactoringAgreementCashReceiptsCollected	3500000	usd
CY2024Q3	blue	Factoring Agreement Receivable Uncollectable Amounts Net Of Accrued Fees FactoringAgreementReceivableUncollectableAmountsNetOfAccruedFees	100000	usd
CY2024Q3	blue	Factoring Agreement Receivable Current Net Of Uncollectible FactoringAgreementReceivableCurrentNetOfUncollectible	1200000	usd
CY2024Q3	blue	Factoring Agreement Gain Loss On Sale Of Invoices FactoringAgreementGainLossOnSaleOfInvoices	-500000	usd
	blue	Factoring Agreement Gain Loss On Sale Of Invoices FactoringAgreementGainLossOnSaleOfInvoices	-1400000	usd
CY2024Q3	blue	Factoring Agreement Servicing Fees FactoringAgreementServicingFees	300000	usd
	blue	Factoring Agreement Servicing Fees FactoringAgreementServicingFees	800000	usd
CY2024Q3	blue	Accrued Clinical And Contract Research Organization Costs Current AccruedClinicalAndContractResearchOrganizationCostsCurrent	21735000	usd
CY2023Q4	blue	Accrued Clinical And Contract Research Organization Costs Current AccruedClinicalAndContractResearchOrganizationCostsCurrent	24824000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15375000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	19972000	usd
CY2024Q3	blue	Accrued Rebates Current AccruedRebatesCurrent	13998000	usd
CY2023Q4	blue	Accrued Rebates Current AccruedRebatesCurrent	5365000	usd
CY2024Q3	blue	Accrued Goods And Services Current AccruedGoodsAndServicesCurrent	1814000	usd
CY2023Q4	blue	Accrued Goods And Services Current AccruedGoodsAndServicesCurrent	8391000	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	10070000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	2531000	usd
CY2024Q3	blue	Other Sublease Rent Liabilities Current OtherSubleaseRentLiabilitiesCurrent	3379000	usd
CY2023Q4	blue	Other Sublease Rent Liabilities Current OtherSubleaseRentLiabilitiesCurrent	3310000	usd
CY2024Q3	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	0	usd
CY2023Q4	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	5600000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3808000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3195000	usd
CY2024Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	70179000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	73188000	usd
CY2024Q3	blue	Lessee Embedded Lease Written Notice Of Termination Term LesseeEmbeddedLeaseWrittenNoticeOfTerminationTerm	P12M
CY2024Q3	blue	Lessee Embedded Lease Extension Term LesseeEmbeddedLeaseExtensionTerm	P5Y
CY2024Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2364000	usd
CY2023Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	4311000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	9421000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	12327000	usd
CY2024Q3	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	14193000	usd
CY2023Q3	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	6459000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	43896000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	16903000	usd
CY2024Q3	blue	Finance Lease Cost FinanceLeaseCost	16557000	usd
CY2023Q3	blue	Finance Lease Cost FinanceLeaseCost	10770000	usd
	blue	Finance Lease Cost FinanceLeaseCost	53317000	usd
	blue	Finance Lease Cost FinanceLeaseCost	29230000	usd
CY2024Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	9486000	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	11470000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	28459000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	34411000	usd
CY2024Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	9486000	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	11470000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	28459000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	34411000	usd
CY2024Q3	us-gaap	Variable Lease Cost VariableLeaseCost	9129000	usd
CY2023Q3	us-gaap	Variable Lease Cost VariableLeaseCost	4186000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	22128000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	16140000	usd
CY2024Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	98000	usd
CY2023Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	43000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	265000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	140000	usd
CY2024Q3	us-gaap	Lease Cost LeaseCost	35270000	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	26469000	usd
	us-gaap	Lease Cost LeaseCost	104169000	usd
	us-gaap	Lease Cost LeaseCost	79921000	usd
CY2024Q3	us-gaap	Sublease Income SubleaseIncome	10219000	usd
CY2023Q3	us-gaap	Sublease Income SubleaseIncome	9742000	usd
	us-gaap	Sublease Income SubleaseIncome	30825000	usd
	us-gaap	Sublease Income SubleaseIncome	30223000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	15323000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	18686000	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	1411000	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	9125000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	69576000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	40299000	usd
CY2024Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y11M1D
CY2023Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M19D
CY2024Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.1256
CY2023Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.1449
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y3M25D
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y2M15D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0697
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0702
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	9151000	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	57718000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	37084000	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	43068000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	35719000	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	2738000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	36742000	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	1673000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	37795000	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	685000	usd
CY2024Q3	blue	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	81986000	usd
CY2024Q3	blue	Finance Lease Liability To Be Paid After Year Four FinanceLeaseLiabilityToBePaidAfterYearFour	0	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	238477000	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	105882000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	45910000	usd
CY2024Q3	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	4036000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	192567000	usd
CY2024Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	101846000	usd
CY2024Q3	us-gaap	Unrecorded Unconditional Purchase Obligation Balance Sheet Amount UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount	60500000	usd
CY2024Q3	us-gaap	Unrecorded Unconditional Purchase Obligation Due In Remainder Of Fiscal Year UnrecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear	294000	usd
CY2024Q3	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On First Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary	15047000	usd
CY2024Q3	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On Second Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary	18733000	usd
CY2024Q3	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On Third Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary	18733000	usd
CY2024Q3	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On Fourth Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary	7668000	usd
CY2024Q3	blue	Unrecorded Unconditional Purchase Obligation To Be Paid After Year Four UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour	0	usd
CY2024Q3	us-gaap	Unrecorded Unconditional Purchase Obligation Balance Sheet Amount UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount	60475000	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2700000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4900000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9700000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16000000.0	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2701000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4868000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9669000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16013000	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2701000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4868000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9669000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16013000	usd
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	1000000	usd
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	1400000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4227000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.16
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3010000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.47
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	905000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	10.52
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6332000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.66
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2290000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	18.54
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	6332000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	8.66
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-100000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0.0	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15694000	shares
CY2024Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15694000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10069000	shares
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10069000	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.10
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.10
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.80
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.80
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.23
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.23
CY2024Q3	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	94	employee
CY2024Q3	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.25
	us-gaap	Restructuring Charges RestructuringCharges	2800000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12281000	usd
CY2023Q3	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	111000	usd
CY2023Q3	us-gaap	Revenues Revenues	12392000	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	9126000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	3266000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	40771000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	58501000	usd
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	99272000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-96006000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2454000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	4311000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10631000	usd
CY2023Q3	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-87232000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-87232000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.80
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.80
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	109098000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	109098000	shares
CY2023Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	137000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	137000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-87095000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21414000	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	249000	usd
	us-gaap	Revenues Revenues	21663000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	21335000	usd
	us-gaap	Gross Profit GrossProfit	328000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	118700000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	131536000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	250236000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	92930000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-156978000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	7961000	usd
	us-gaap	Interest Expense InterestExpense	12331000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	30177000	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-131171000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-80000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-131091000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.23
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.23
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106924000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106924000	shares
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0.0	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1843000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1843000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-129248000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	134333000	usd
CY2023Q1	blue	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	-195000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	227000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	130291000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5843000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	984000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	18930000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	290420000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	290420000	usd
CY2023Q2	blue	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	0	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	77000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6388000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	722000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-62789000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	234818000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	234818000	usd
CY2023Q3	blue	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	0	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-50000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5153000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	137000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-87232000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	152834000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-131091000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	19660000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	16013000	usd
	blue	Noncash Research And Development Expense Finance Lease NoncashResearchAndDevelopmentExpenseFinanceLease	22223000	usd
	blue	Noncash Lease Expense NoncashLeaseExpense	23965000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	92930000	usd
	blue	Inventory Excess Valuation Reserves InventoryExcessValuationReserves	9202000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-100000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1062000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	14600000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2117000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	26197000	usd
	blue	Lessee Increase Decrease In Operating Lease Right Of Use Asset LesseeIncreaseDecreaseInOperatingLeaseRightOfUseAsset	0	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1712000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5709000	usd
	blue	Increase Decrease Accrued Interest Payable Under Finance Lease IncreaseDecreaseAccruedInterestPayableUnderFinanceLease	-3203000	usd
	blue	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-18686000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-248000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-180910000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2975000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	43297000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	99521000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	5853000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	868000	usd
	us-gaap	Proceeds From Sales Of Assets Investing Activities ProceedsFromSalesOfAssetsInvestingActivities	92930000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	151164000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	93000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	40299000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	89670000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	59924000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	158445000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	218369000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	165347000	usd
CY2023Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	8885000	usd
CY2023Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	44137000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	218369000	usd
	blue	Right Of Use Asset Obtained In Exchange For Operating Lease Liability Including Adjustments For Remeasurement RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityIncludingAdjustmentsForRemeasurement	-708000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	941000	usd
	blue	Offering Expenses Included In Accounts Payable And Accrued Expenses OfferingExpensesIncludedInAccountsPayableAndAccruedExpenses	248000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	21508000	usd
	blue	Increase Reduction Of Right Of Use Asset And Associated Operating Lease Liability Due To Lease Reassessment IncreaseReductionOfRightOfUseAssetAndAssociatedOperatingLeaseLiabilityDueToLeaseReassessment	0	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	5000	usd
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001293971-24-000079-index-headers.html	Edgar Link	pending
0001293971-24-000079-index.html	Edgar Link	pending
0001293971-24-000079.txt	Edgar Link	pending
0001293971-24-000079-xbrl.zip	Edgar Link	pending
blue-20240930.htm	Edgar Link	pending
blue-20240930.xsd	Edgar Link	pending
blue-20240930xex104.htm	Edgar Link	pending
blue-20240930xex105.htm	Edgar Link	pending
blue-20240930xex311.htm	Edgar Link	pending
blue-20240930xex312.htm	Edgar Link	pending
blue-20240930xex321.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
blue-20240930_cal.xml	Edgar Link	unprocessable
blue-20240930_def.xml	Edgar Link	unprocessable
blue-20240930_lab.xml	Edgar Link	unprocessable
blue-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
blue-20240930_htm.xml	Edgar Link	completed
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BLUE
bluebird bio, Inc. Stock $blue

2024 Q4 Form 10-Q Financial Statement

#000129397124000079 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BLUE bluebird bio, Inc. Stock $blue

2024 Q4 Form 10-Q Financial Statement

#000129397124000079 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BLUE
bluebird bio, Inc. Stock $blue